Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

scientific article published on 01 December 2000

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1089/10430340050207957
P698PubMed publication ID11119418

P2093author name stringFong Y
Kooby DA
Petrowsky H
Hawkins WG
Zager JS
Johnson P
Bennett JJ
Burt BM
Delman KA
Horsburgh BC
McAuliffe PF
P433issue18
P921main subjectoncolytic virusQ1560099
P304page(s)2465-2472
P577publication date2000-12-01
P1433published inHuman Gene TherapyQ15757580
P1476titleEffects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy
P478volume11

Reverse relations

cites work (P2860)
Q33713249A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer
Q39557591Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.
Q35043106Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes
Q37132189Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice
Q78392743Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer
Q54714678Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy.
Q37099738Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters
Q35131235Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells
Q45731236Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer
Q91521080Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model
Q35116166Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer
Q35126267Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review
Q36444443Herpes simplex virus 1 (HSV-1) for cancer treatment
Q81444939Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy
Q33713824Herpes simplex virus oncolytic therapy for pediatric malignancies
Q38500301Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy
Q35699072ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.
Q37899230Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress
Q35216661Oncolytic herpes simplex virus for tumor therapy
Q28202611Oncolytic herpes simplex virus vectors for cancer virotherapy
Q35613495Oncolytic herpes viruses as a potential mechanism for cancer therapy.
Q35832074Oncolytic virotherapy for advanced liver tumours.
Q36769180Oncolytic viruses in cancer therapy
Q36109704Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.
Q24633957Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver
Q44124151Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene
Q37759934Regional liver therapy using oncolytic virus to target hepatic colorectal metastases
Q36086213Replication-Competent Controlled Herpes Simplex Virus
Q37596491Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice
Q41919532Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses
Q45733718The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma
Q34423157Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta
Q36920216Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
Q33976318VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy
Q45880904Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors
Q64378232Viral oncolysis
Q39786869Viral vector-induced expression of bone morphogenetic protein 2 produces inhibition of tumor growth and bone differentiation of stem cells

Search more.